Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma (Q73867868)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

2

Reinhard Dummer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

9

Axel Hauschild

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

Norbert H Brockmeyer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Helga Konrad

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

J-O Busch

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Martin Kaatz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Burkhard Knopf

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Hans-Jürgen Koch

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

English

0 references

publication date

1 September 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

98

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

993-1001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Granulomatous slack skin or granulomatous mycosis fungoides -- a case report. Complete response to percutaneous radiation and interferon alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Anthracyclines in the treatment of cancer. An overview

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Clinical uses of pegylated pharmaceuticals in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Long-term remission of recalcitrant tumour-stage mycosis fungoides following chemotherapy with pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

[Endocrine orbitopathy: comparison of the long-term result and classification after radiotherapy].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Safety aspects of pegylated liposomal doxorubicin in patients with cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Cutaneous T-cell lymphoma (mycosis fungoides)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Photopheresis therapy for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Pentostatin therapy of T-cell lymphomas with cutaneous manifestations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Lack of vesicant injury following extravasation of liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11593

7 January 2021

Identifiers

DOI

10.1002/CNCR.11593

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942567%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference